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Abstract 26 
Scope: To investigate the effects of n-3 fatty acid supplements, both marine and plant-based, 27 
on glycemic traits in Chinese type 2 diabetes (T2D) patients. 28 
Method and results: In a double-blind randomized controlled trial, 185 recruited Chinese 29 
T2D patients were randomized to either fish oil (FO, n=63), flaxseed oil (FSO, n=61) or corn 30 
oil group (CO, served as control group, n=61) for 180 days. The patients were asked to take 31 
corresponding oil capsules (4 capsules/day), which totally provided 2 g/day of 32 
eicosapentaenoic acid + docosahexaenoic acid in FO group and 2.5 g/day of alpha-linolenic 33 
acid in FSO group. No group×time interaction was observed for HOMA-insulin resistance, 34 
fasting insulin or glucose. Significant group×time interaction (P =0.035) was observed for 35 
glycated haemoglobin (HbA1c), with HbA1c decreased in FO group compared with CO 36 
group (P=0.037). We also found significant group×time interactions for lipid traits, including 37 
low-density lipoprotein cholesterol (P=0.043), total cholesterol (TC) (P=0.021), total 38 
cholesterol/ high-density lipoprotein cholesterol (TC/HDL-C) (P=0.009) and triacylglycerol 39 
(TG) (P=0.003), with the lipid profiles improved in FO group. No significant effects of FSO 40 
on glycemic traits or blood lipids were observed.  41 
Conclusions: Marine n-3 PUFA supplements may improve glycemic control and lipid 42 
profiles among Chinese type 2 diabetic patients. 43 
 44 
Clinical trial reg. no. NCT01857167, clinicaltrials.gov 45 
 46 
 47 
 48 
 49 
 50 
 51 
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Introduction 52 
The epidemic of type 2 diabetes (T2D) continues to grow worldwide, especially in 53 
developing countries, such as China and India [1]. It is projected from a nationally 54 
representative samples that up to 113.9 million and 493.4 million Chinese adults have 55 
diabetes and prediabetes, respectively [2]. Epidemiologic studies consistently show that T2D 56 
is largely preventable through diet and lifestyle modification [1, 3]. One type of the candidate 57 
dietary factors is long-chain marine sources of n-3 polyunsaturated fatty acids (PUFA) 58 
(eicosapentaenoic acid [EPA, C20:5n3], docosapentaenoic acid [DPA, C22:5n3] and 59 
docosahexaenoic acid [DHA, C22:6n3]), as indicated by a number of rodent models, which 60 
consistently suggest improvement of insulin sensitivity by marine n-3 PUFA [4-6]. Of note, 61 
most rodent models use amounts of n-3 PUFA that are in considerable excess (on a pro-rata 62 
basis) to that allowed in human [7]; and therefore the results may not be applicable among 63 
humans. Yet, results from human observational and intervention studies remain inconclusive 64 
[8-10]. Meta-analyses suggest that marine n-3 PUFA are inversely associated with risk of 65 
T2D in Asian populations, including Chinese populations [8, 11, 12]. Furthermore, plasma 66 
marine n-3 PUFA are inversely associated with insulin resistance in Chinese T2D patients 67 
[13]. However, in a Cochrane systematic review and meta-analysis of trials involving n-3 68 
PUFA treatment in T2D patients [14], marine n-3 PUFA supplements do not affect insulin 69 
sensitivity or glucose metabolism of these patients. Of note, no included or excluded trials in 70 
the meta-analysis are conducted among Chinese [14].  Another two meta-analyses of 71 
randomized controlled trials also suggests a lack of marine n-3 PUFA effect on insulin 72 
sensitivity in T2D patients, with only one small trial among Chinese [9, 15].  73 
In addition to marine n-3 PUFA, alpha-linolenic acid (ALA, C18:3n3), a plant-based n-3 74 
PUFA, has also shown inverse association with T2D in Chinese populations in observational 75 
studies [16, 17]. However, to the best of our knowledge, there is no published randomized 76 
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controlled trial among Chinese T2D patients for the ALA (mainly from flaxseed oil) 77 
intervention. 78 
 79 
Therefore, to fill the gap and to confirm the results generated from observational studies, a 80 
large randomized controlled trial of n-3 PUFA supplements in Chinese T2D patients is highly 81 
necessary. In the present study, we conducted a randomized, multicenter, double-blind, 82 
placebo-controlled trial to investigate the effects of n-3 PUFA supplements, both marine and 83 
plant-based, on glycemic traits in Chinese T2D patients. 84 
 85 
Materials and Methods  86 
The trial was registered at ClinicalTrials.gov (No. NCT01857167). The trial was approved by 87 
the Ethics Committee of College of Biosystem Engineering and Food Science at Zhejiang 88 
University (No. 2013011). All the participants gave written informed consent. 89 
 90 
Experiment oil capsule preparation 91 
We standardized each of fish oil (FO), flaxseed oil (FSO) or corn oil (CO) capsules to one 92 
gram with identical appearance. Each FO capsule provided 500mg of EPA + DHA (EPA: 93 
DHA=3:2), and other major fatty acids in each FO capsule were C16:0 (71.4mg), C18:1n-9 94 
(58.4mg), C16:1 (56mg), C20:0 (39.4mg) and C14:0 (34.6mg). Each FSO capsule contained 95 
630mg of ALA, 155mg of C18:2n-6 and 137mg of C18:1n-9. Major fatty acids in each CO 96 
capsule were C18:2n-6 (534mg), C18:1n-9 (299mg) and C16:0 (121mg). All the capsules 97 
were made in the Neptunus Bioengineering Co., Ltd (Hangzhou, China). All the capsules 98 
were kept in white bottles (90 capsules/bottle), which were labeled as Oil A, Oil B and Oil C 99 
for the three types of capsules. None of the participants or the nurses/physicians in the study 100 
centers knew the oil types during the intervention.  101 
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 102 
Inclusion and exclusion criteria of the study participants 103 
The inclusion criteria were (1) fasting blood glucose > 7.0 mmol/L or on use of diabetic 104 
medications; (2) between 35 and 80 years old for men and between post-menopausal and 80 105 
years old for women. The exclusion criteria were (1) having familial hyperlipemia or with 106 
blood triacylglycerol (TG) concentrations >4.56 mmol/L; (2) a history of hepatic or kidney 107 
disease, or any type of cancer; (3) participation in anther clinical trial within 30 days prior to 108 
screening.  109 
 110 
Randomization of the participants and intervention 111 
Two hundred and fifty-two potentially adults with known T2D status were screened in three 112 
study centers between June 2013 to June 2014. One hundred and eighty-five T2D patients 113 
were recruited based on the inclusion and exclusion criteria in the three study centers: Wuhan 114 
(Central China) (n=59), Changshan (Southeast China) (n=47) and Lanzhou (Western China) 115 
(n=79).  116 
 117 
 All the included participants were randomly allocated to one of the three treatments by 118 
computer-generated random numbers with a block size of six: FO group (n=63), FSO group 119 
(n=61) and CO group (n=61). Allocation sequence was generated by JSZ. Doctors/nurses at 120 
each study center enrolled and assigned participants to the intervention groups. The 121 
participants in each of the trial arms were required to take 4 capsules/day, which would 122 
totally provide 2 g/day of EPA+DHA in FO group or 2.5 g/day of ALA in FSO group. The 123 
dosage of n-3 PUFA supplements were consistent with those used in previous trials [10]. The 124 
duration of the intervention was 180 days. All the patients were given four bottles of capsules 125 
at baseline, and given another four bottles at 90 days of the intervention when they came back 126 
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to the study centers for health examination. At visit of 180 days of intervention, patients came 127 
back to the study centers for the final on-site examination. About 84.3% (n=157) of included 128 
patients took diabetic medications, with 37 patients (13, 12 and 12 for FO, FSO and CO 129 
group, respectively) using insulin only, 83 patients (27, 31 and 25 for FO, FSO and CO group, 130 
respectively) using oral glucose-lowering drugs only, and 36 patients (11, 10 and 15 for FO, 131 
FSO and CO group, respectively) using both insulin and glucose-lowering drug. All the 132 
patients were asked to maintain their usual diet, lifestyle or use of prescribed medications, 133 
and avoid use of n-3 fatty acid supplements during the intervention.  134 
 135 
Measurements of biochemical parameters and erythrocyte fatty acids 136 
We took fasting blood samples (10 mL) of all the participants at baseline, day 90 and day 180 137 
of intervention. Serum high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein 138 
cholesterol (LDL-C), total cholesterol, TG, glucose, uric acid, blood urea nitrogen (BUN), 139 
creatinine, liver function markers (alanine transaminase [ALT], aspartate transaminase 140 
[AST]), blood total protein, globulin (GLB), albumin (ALB), total bilirubin (TBIL), direct 141 
bilirubin (DBIL), indirect bilirubin (IDBIL) were measured by commercially available kits on 142 
HITACHI 7020 chemistry analyzer using enzyme-based colorimetric test supplied by Diasys 143 
Diagnostic Systems (Shanghai) Co., Ltd. at each of the study centers. Serum insulin was 144 
measured by ARCHITECT insulin reagent kit (Abbott Laboratories, Abbott Park, IL, USA). 145 
Using fasting glucose and insulin, homeostatic model assessment of insulin resistance 146 
(HOMA-IR) was calculated by using the formula: glucose (mmol/L) × insulin (mU/L)/22.5 147 
[18]. HOMA-IR, but not HOMA2 model, was used to represent insulin resistance as it was 148 
more widely used in Chinese populations, and therefore more comparable among related 149 
studies in China. Blood glycated hemoglobin A1c (HbA1c) was measured by automated 150 
Hemoglobin A1c Analyzer. Blood samples not immediately measured were stored under -151 
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80
o
C for further analysis. Anthropometric parameters, including weight, height, waist and hip 152 
circumference, were measured at baseline and end-point of the intervention. 153 
 154 
Compliance of the patients to the intervention was evaluated by measurement of erythrocyte 155 
phospholipid fatty acid compositions at baseline and end-point of the intervention, and by 156 
counting the empty bottles they returned to the study centers at day 90 and 180. Additionally, 157 
trained nurses contacted patients via phone once per month to record their compliance of the 158 
previous month and to remind them to take the capsules. Erythrocyte phospholipid fatty acids 159 
were measured by gas chromatography as previous described [19]. Briefly, we extracted total 160 
lipids from erythrocytes with chloroform/methanol (1:1), and separated phospholipid fraction 161 
from the total lipids by thin-layer chromatography. Then, we converted the phospholipid fatty 162 
acids to methylester and extracted them into n-hexane and dried on anhydrous Na2SO4. 163 
Finally, we filtered fatty acid methylesters by Sep-Pak Silica column before gas 164 
chromatography separation and analysis. 165 
 166 
Statistical analysis 167 
We conducted all the statistical analyses in Stata (version 13; StataCorp, College Station, TX, 168 
USA). The total sample size was calculated based on 80% power (αtwo-tailed=0.05) to detect 169 
difference in HOMA-IR by 20% or 0.63 (SD=1.1) between groups (n=150, 50/group), 170 
considering 20% drop out rate (n=187, 62/group), based on our previous work [20]. This 171 
sample size (n=50 /group) will also enable us to have 84% power (αtwo-tailed=0.05) to detect 172 
difference in HbA1c by 20% or 12 mmol/mol (SD=20) between groups. 173 
 174 
All the outcomes variables were checked for the normal distribution, and were log 175 
transformed if they were not normal distributed (HOMA-IR, glucose, insulin, HbA1c and TG 176 
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were natural log transformed). One-way ANOVA (for continuous variables) or Chi-square 177 
test (for categorical variables) was performed to test the group difference at baseline. 178 
Difference in change of the three fatty acid compositions for FO or FSO compared with CO 179 
group was examined by linear regression, adjusting for age, sex, study center and baseline 180 
BMI and baseline corresponding fatty acid composition. 181 
 182 
Following an intention-to-treat principal, linear mixed models were used to compare 183 
differences between intervention groups in four glycemic traits (HOMA-IR, insulin, glucose, 184 
HbA1c) overtime (day 0, 90 and 180).  The mixed model analysis without any ad hoc 185 
imputation for missing data would provide equal or more power than dose analysis with data 186 
imputation [21]. Time since baseline randomization was included in the model as a 187 
categorical variable (day 0, 90 and 180), and the group×time interaction was treated as the 188 
fixed effect in the model and was the primary effect of interest. Other potential confounders 189 
included in the model as fixed effects were age, sex, study center and baseline BMI. 190 
Sensitivity analysis was conducted (1) by including only two time points (day 0 and 180) in 191 
the linear mixed models; (2) by including baseline value of corresponding outcome as a 192 
covariate in the linear mixed models.  193 
 194 
In addition to the primary analyses on glycemic traits, we performed secondary analyses on 195 
lipid traits, including HDL-C, LDL-C, TC, TC/HDL-C and TG using the linear mixed models. 196 
If significant time × group interaction was observed for primary or secondary analyses, we 197 
conducted post-hoc analyses to examine the group × time interaction between FO and CO, 198 
between FO and FSO, and between FSO and CO, respectively, based on the linear mixed 199 
models. P-value (two-tailed) <0.05 was considered significant. 200 
 201 
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Results 202 
At baseline, we did not observe any significant difference in blood lipids or glycemic traits 203 
between participants of the three intervention groups (Table 1). During the intervention, five 204 
participants in the FO group, eight participants in the FSO group and six participants in the 205 
CO group dropped out of the trials, leaving 58, 53 and 55 participants in the FO, FSO and CO 206 
group, respectively (Figure 1). 207 
 208 
Erythrocyte EPA and DHA was significantly increased in the FO group compared with the 209 
CO group (P<0.001 for both fatty acids) (Figure 2). FSO group, compared with CO group, 210 
had significant increased composition of ALA (P=0.043), but non-significant increase of EPA 211 
(P=0.084) and DHA (P=0.056). EPA was significantly increased in FO compared with FSO 212 
group (P=0.001). 213 
  214 
No significant difference among the three groups was observed on fasting serum glucose, 215 
insulin or HOMA-IR (Table 2). However, we found significant interaction between study 216 
groups (3 groups) and time (3 time points) for HbA1c (P=0.035). Post-hoc analysis showed 217 
that HbA1c was significantly decreased in FO group (P=0.037) but not FSO group (P=0.30), 218 
compared with CO group. Sensitivity analysis by including 2 time points (day 0 and 180) 219 
found similar tendency that HbA1c decreased in FO group (P=0.088) and in FSO group 220 
(P=0.152), compared with CO group. Further sensitivity analysis by including baseline 221 
outcome value as a covariate found that FO compared with CO group, showed a stronger 222 
statistical significance in the HbA1c (P=0.009 from the full analysis including 3 time points; 223 
P=0.029 from the restricted analysis including 2 time points [day 0 and day 180]), while no 224 
significant difference in the HbA1c (P=0.23 and 0.06 from the full analysis and restricted 225 
analysis respectively) observed for FSO compared with CO group. No significant 226 
Page 10 of 28
Wiley-VCH
Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
10 
 
results/material changes were found for other glycemic traits in FO or FSO group in the 227 
above two steps of sensitivity analyses.  228 
 229 
We found significant time by group interaction for each of serum LDL-C (P=0.043), TC 230 
(P=0.021), TC/HDL-C (P=0.009) and TG (P=0.003), but not for HDL-C (Table 3). In the 231 
post-hoc analyses, serum concentrations of TC (P=0.029), TC/HDL-C (P=0.038) and TG 232 
(P=0.001) were significantly decreased in FO group compared with that in CO group, but 233 
with no statistical significance on LDL-C (P=0.081). FO group compared with FSO group, 234 
had significant decrease of LDL-C (P=0.025), TC (P=0.007), TC/HDL-C (P<0.001) and TG 235 
(P=0.043) after the intervention. No significant difference between FSO and CO groups was 236 
found for any blood lipid trait. No significantly different change between treatments during 237 
the intervention was observed for other biochemical parameters, except for IDBIL (P=0.047) 238 
(Table 4). 239 
 240 
Discussion 241 
To the best of our knowledge, the present randomized controlled trial was among the first to 242 
examine the effect of both marine and plant-based n-3 PUFA supplements on Chinese T2D 243 
patents. Our trial also had larger sample size than most of previous trial in other population 244 
settings. We found that FO supplements may potentially improve glycemic control in the T2D 245 
patients in terms of decreasing HbA1c, a marker of blood glucose status over the past few 246 
months. Moreover, FO consistently lowered blood lipids in these patients, including TC, 247 
LDL-C and TC/HDL-C. No significant effects on glycemic traits or blood lipids were found 248 
in patients taking FSO supplements. 249 
 250 
Fish oil supplements were found to increase blood glucose levels with borderline significance 251 
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among T2D patients in an early meta-analysis [22]. In addition, every one g/day increase of 252 
EPA and DHA was significantly associated with 0.38% and 0.6% increase of HbA1c, 253 
respectively, in T2D patients [22]. However, an updated Cochrane review of n-3 PUFA 254 
intervention among T2D patients based on 23 randomized controlled trial (1075 participants) 255 
showed that n-3 PUFA supplements did not have any significant effect on glycemic traits, 256 
including fasting insulin, glucose and HbA1c [14]. In several other reviews of n-3 PUFA 257 
supplements, the authors suggested no benefit of n-3 PUFA on glycemic traits or insulin 258 
sensitivity among T2D patients [10]. Of note, all of the trials included in the above meta-259 
analyses or review [9, 10, 14] came from Western populations, with no trials from Asian 260 
populations (except for one from India). These results were consistent with that from meta-261 
analyses of prospective cohort studies, which suggested that marine n-3 PUFA/fish intake 262 
showed null or even positive association with T2D risk in Western populations [8, 11]. In 263 
contrast, marine n-3 PUFA intake was associated with lower risk of T2D in Asian populations 264 
[8, 11]. Furthermore, the only randomized controlled trial in the Asian Indian population [23] 265 
in the aforementioned meta-analysis [14] suggested that n-3 PUFA could improve glycemic 266 
status. Recently, several randomized controlled trials of n-3 PUFA supplements among T2D 267 
patients have been conducted in Asian countries (from Iran and Japan) [24-26]. For example, 268 
in a randomized double-blind placebo-controlled trial among 81 T2D patients in Iran, n-3 269 
PUFA supplementation for 2 months significantly decreased HbA1c compared with control 270 
group [26]. Among another trial of 67 Iranian T2D patients over a period of 3-month 271 
intervention [24], n-3 PUFA (EPA) supplementation improved glycemic control by 272 
decreasing fasting serum insulin, glucose, HbA1c and HOMA-IR. Furthermore, in a 273 
randomized controlled trial among 30 elderly Japanese T2D patients, EPA/DHA-rich liquid 274 
diet, compared with liquid diet lacking EPA/DHA, significantly decreased fasting plasma 275 
glucose and HbA1c over a period of 3 months [25]. These new evidence suggested that n-3 276 
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PUFA supplements could potentially improve glycemic control in Asian populations, while 277 
no evidence was available among Chinese populations prior to our present trial.  278 
 279 
Our current trial supported that marine n-3 PUFA supplements may improve glycemic control 280 
by decreasing HbA1c level. The reason for the non-significant change for HOMA-IR or 281 
fasting glucose was not clear, which may be due to the influence of regular oral drug use or 282 
insulin injection days before the blood draw. We also observed that HOMA-IR, insulin and 283 
glucose level were lowest at 90 days. This may be due to the decrease of compliance in the 284 
late stage of the trial or some unknown confounding factors. In addition, we found that 285 
HbA1c in FSO group continuously decreased from baseline to day 90 and subsequently to 286 
day 180; while in FO group it decreased from baseline to day 90 and then increased at day 287 
180. This observation may be because of the poorer compliance after day 90 in FO group, or 288 
because of the fact that the degree of response to either treatment has reached a plateau at the 289 
HbA1c value of around 54 mmol/mol. Nevertheless, HbA1c is a stable marker of glucose 290 
status over several months, and the decreased level of HbA1c indicates improved glycemic 291 
control after the marine n-3 PUFA supplements. The disparate findings for marine n-3 PUFA 292 
with glycemic control and T2D in Asian and Western populations may be due to the different 293 
genetic backgrounds. For example, in a recent study [27], researchers find that an adaptive 294 
genetic polymorphism within FADS2 gene conferred an adaptive advantage in Asians because 295 
of the traditional plant-based diet practice, which suggests that Asians are more likely to 296 
synthesize long-chain PUFA from plant PUFA precursors. Based on the aforementioned 297 
evidence, we therefore hypothesized that Asians may be more sensitive to marine n-3 PUFA 298 
in terms of glycemic control compared with Western populations, which warrants further 299 
investigation. 300 
 301 
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In contrast to glycemic traits, previous meta-analyses consistently supported that marine n-3 302 
PUFA improved lipid profiles by reducing blood TG level [14, 22] among T2D patients. 303 
However, both of these meta-analyses suggested that n-3 PUFA may increase serum LDL-C 304 
concentration among T2D patients; while no significant change in TC or HDL-C was 305 
observed after n-3 PUFA supplements [14, 22]. In the secondary analyses of the present study, 306 
TG, TC and TC/HDL-C were significantly decreased in FO group compared with CO group. 307 
In addition, FO had the tendency to decrease LDL-C compared with the CO. The present 308 
results suggested that, in Chinese T2D patients, beneficial effect of n-3 PUFA on blood lipids 309 
was not limited to TG, but also to other lipid profiles, such as TC, TC/HDL-C and potentially 310 
LDL-C. The reason for the difference in TC and LDL-C between the present results and that 311 
of previous meta-analyses was not clear. It may be that the present study had longer 312 
intervention period than most of previous randomized trials included in the meta-analyses [14, 313 
22]. Furthermore, we did not collect information on statin use for the patients, which may 314 
potentially bias the lipid response to n-3 PUFA intervention. Nevertheless, these results 315 
indicated that fish oil might play an important role in the prevention of cardiovascular events, 316 
a most important complication of T2D. We noticed a slightly different response of lipids to n-317 
3 PUFA at day 90 and day 180, which suggested that the effects of n-3 PUFA on blood lipids 318 
may have some optimal threshold in terms of intervention period (reaching optimal blood n-3 319 
PUFA levels), which warrants further investigation. 320 
 321 
Different from FO, the present study did not observed any significant effect of FSO 322 
supplements, source of a plant-based n-3 PUFA: ALA, on glycemic traits or lipid profiles. 323 
Our results were consistent with several previous trials. In two randomized controlled trials of 324 
FSO supplements among T2D individuals [28, 29], 7.4g/d and 5g/d of ALA was used in the 325 
trial arm of each study. However, there was no significant change of glycemic traits in 326 
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response to FSO supplements in the two studies. Given that dose of ALA used in the present 327 
study (2.5g/d) was much lower than that of previous trials [28, 29], it could be postulated that 328 
in the present study we would observed no significant effect of ALA supplements on 329 
glycemic traits as consistent with the previous trials [28, 29]. Yet, further randomized trials of 330 
higher flaxseed oil/ALA dose are needed to investigate the effect of FSO/ALA on Chinese 331 
T2D patients. 332 
 333 
The beneficial effects of the marine n-3 PUFA on glycemic control and glucose homeostasis 334 
are biological plausible and may involve various mechanisms. For example, with the 335 
increasing incorporation of marine n-3 PUFA into cell membranes via supplementation, the 336 
membrane fluidity will be increased, leading to increased insulin sensitivity [30]. Marine n-3 337 
PUFA may also improve glucose homeostasis through regulating inflammatory status [31, 32]. 338 
In addition, a variety of animal models have suggested that marine n-3 PUFA may improve 339 
insulin sensitivity and glucose homeostasis by influencing insulin signaling pathway [33-36].  340 
 341 
The present study has several strengths. First, the sample size of the present trial provided 342 
sufficient power to examine the effect of n-3 PUFA supplements on glycemic traits. Second, 343 
study duration was longer than most of previous trials in the T2D patients. Third, this was a 344 
multicenter trial, which represented participants from Western, Central and Southeast China. 345 
The limitation of the present trial was that 180-day of intervention was still too short for us to 346 
examine the effect of n-3 PUFA supplements on T2D complications, such as cardiovascular 347 
events among the patients. In addition, we suggested that the patients maintain their usual diet 348 
and physical activity, but did not monitor their lifestyles during the intervention, although we 349 
obtained oral agreements from the patients that they would not change their diet or lifestyles 350 
during the intervention. Third, 84.3% of study participants took diabetic medications, which 351 
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may be a potential source of confounding to the present trial. Yet, the distribution of 352 
medications used was similar among groups, and unlikely to affect the study results. Fourth, 353 
the repeated measure approach may not capture the potentially specific response at day 90 354 
and at day 180 to the treatments, which may influence the overall results. This speculation 355 
was supported by our sensitivity analysis of including only 2 time points (day 0 and day180) 356 
in the models that the effect of FO was attenuated, while effect of FSO strengthened. Last, we 357 
did not randomize the participants based on HbA1c at baseline, which may potentially affect 358 
the effect of n-3 supplements on HbA1c, a main outcome of this trial. Future researchers in 359 
this area need to balance trial arms for the main outcomes at baseline. 360 
 361 
In conclusion, the present randomized controlled trial suggested that marine n-3 PUFA 362 
supplements for 180 days potentially improved glycemic control in Chinese T2D patients. 363 
This study provides new evidence of using marine n-3 PUFA for the glycemic control of 364 
Chinese T2D patients; however, there is no convincing evidence showing that marine n-3 365 
PUFA are superior to plant-based n-3 PUFA. More studies with longer follow-up duration 366 
and larger sample size in Chinese populations are warranted to replicate and confirm the 367 
results of the present study. 368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
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Table 1 Baseline characteristics of study participants involved in the randomized 
controlled trial 
  Fish oil (n=63) Flaxseed oil (n=61) Corn oil (n=61) 
Age, y 59.7±8.8 59.7±11.1 59.1±10 
Women, n (%) 25 (39.7) 41 (67.2) 32 (52.4)* 
Weight, kg 68.4±11.5 63.8±11.5 68.9±15.2 
BMI, kg/m
2
 24.7±2.8 24.7±3.9 25.5±4.1 
SBP, mmHg 137.2±20.2 138.3±18.6 133.7±21.4 
DBP, mmHg 78.2±10.5 78.6±8.1 79.5±14.9 
HDL-C, mmol/L 1.14±0.3 1.16±0.29 1.19±0.20 
LDL-C, mmol/L 2.97±0.80 2.89±0.85 3.05±0.85 
TC, mmol/L 4.66±0.96 4.68±0.96 4.88±1.01 
TC/HDL-C 4.28±1.05 4.23±1.13 4.17±0.92 
TG, mmol/L 1.68±0.74 1.93±1.30 1.85±0.97 
 
Values are presented as mean ± SD, except for women (n). *P<0.05 indicated significantly 
different between the three trial arms. One-way ANOVA (for continuous variables) or Chi-
square test (for categorical variables) was performed to test the group difference at baseline. 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, 
triacylglycerol 
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Table 2 Effect of n-3 PUFA supplements on glycemic traits in Chinese patients with type 
2 diabetes 
  Time Fish oil 
Flaxseed 
oil Corn oil P-time 
P-
group 
P-time×group 
interaction 
Fasting glucose, 
mmol/L day 0 8.18±3.03 8.61±3.64 8.31±3.63 0.221 0.811 0.703 
  day 90 7.60±1.93 8.23±2.83 7.71±2.37       
  day 180 8.46±3.02 8.16±2.70 8.22±2.51       
Fasting insulin, 
mU/L day 0 14.7±8.7 20.3±18 16.5±16.1 <0.001 0.069 0.281 
  day 90 11.4±10.6 13.1±10.8 11.5±9.67       
  day 180 11.6±6.76 15.6±11.3 18.1±19.8       
HOMA-IR day 0 5.48±3.97 7.57±6.39 6.21±5.89 <0.001 0.107 0.404 
  day 90 4.19±4.76 5.10±4.62 4.00±4.57       
  day 180 4.68±4.12 5.74±4.67 6.46±6.46       
HbA1c, 
mmol/mol day 0 63.9±22.9 62.3±20.8 57.6±16.4 <0.001 0.571 0.035 
day 90 52.7±13.8 59.2±17.1 56.2±17.2 
day 180 54.4±13.4a 54.2±14ab 55.0±16.4b 
Values are presented as mean ± SD. Groups sharing the same superscript (a or b) have no 
significant difference from each other in the post-hoc analysis (P≥0.05). HOMA-IR, 
homeostatic model assessment of insulin resistance; HbA1c, glycated hemoglobin A1c. 
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Table 3 Effect of n-3 PUFA on blood lipids in Chinese patients with type 2 diabetes 
    Fish oil Flaxseed oil Corn oil P-time 
P-
group 
P-
time×group 
interaction 
HDL-C, 
mmol/L day 0 1.14±0.3 1.16±0.29 1.19±0.20 <0.001 0.112 0.436 
  day 90 1.25±0.33 1.20±0.33 1.27±0.25       
  day 180 1.23±0.30 1.22±0.29 1.25±0.25       
LDL-C, 
mmol/L day 0 2.97±0.80 2.89±0.85 3.05±0.85 0.017 0.055 0.043 
  day 90 2.92±0.78 2.85±0.80 3.14±0.96       
  day 180 2.62±0.81a 2.80±0.72b 2.99±0.90ab       
TC, mmol/L day 0 4.66±0.96 4.68±0.96 4.88±1.01 0.25 0.016 0.021 
  day 90 4.56±0.99 4.83±0.82 5.04±1.00       
  day 180 4.50±1.00a 4.90±0.85b 5.04±1.10b       
TC/HDL-C day 0 4.28±1.05 4.23±1.13 4.17±0.92 0.112 0.241 0.009 
  day 90 3.81±0.98 4.30±1.40 4.03±0.84       
  day 180 3.82±1.02a 4.22±1.12b 4.19±1.46b       
TG, mmol/L day 0 1.68±0.74 1.93±1.30 1.85±0.97 0.006 0.057 0.003 
  day 90 1.34±0.56 1.96±1.46 1.78±1.03       
  day 180 1.45±0.75a 1.94±1.15b 1.75±0.87b       
Values are presented as mean ± SD. Groups sharing the same superscript (a or b) have no 
significant difference from each other in the post-hoc analysis (P≥0.05). HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total 
cholesterol; TG, triacylglycerol. 
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Table 4 Effect of n-3 PUFA supplements on liver and kidney function markers and other 
blood parameters. 
  Time Fish oil Flaxseed oil Corn oil P-time P-group 
P-
time×group 
interaction 
BUN day 0 6.04±2.15 6.02±1.88 5.54±1.36 0.017 0.375 0.677 
  day 180 6.10±2.24 6.31±1.62 5.88±1.60       
Creatinine day 0 75.0±28.0 64.6±22.0 66.1±23.5 0.905 0.301 0.387 
  day 180 73.8±36.2 65.9±22.8 68.1±34.1       
Uric acid day 0 322.4±86.9 322.0±78.9 320.3±98.4 0.485 0.95 0.207 
  day 180 332.4±81.1 313.6±88.7 307.8±73.6       
ALT day 0 28.0±17.8 31.1±22.6 28.2±14.8 0.074 0.36 0.839 
  day 180 29.5±16.8 30.6±25.9 31.6±18.8       
AST day 0 26.6±10.8 29.1±16.2 25.7±8.00 0.091 0.535 0.774 
  day 180 25.1±11.0 26.2±11.7 25.4±10.3       
TBIL day 0 12.7±5.72 12.2±6.32 13.4±6.3 0.148 0.077 0.151 
  day 180 11.2±4.39 12.4±6.94 15.5±20.0       
DBIL day 0 5.28±2.54 5.02±2.04 5.36±2.24 <0.001 0.632 0.344 
  day 180 4.47±1.47 4.76±2.09 4.49±1.54       
IBIL day 0 7.92±4.18 8.35±4.92 8.72±4.91 0.155 0.181 0.047 
  day 180 6.69±3.48a 7.90±4.44ab 8.71±4.68b       
TP  day 0 70.0±5.60 71.4±8.16 71.1±6.84 0.055 0.43 0.90 
  day 180 71.7±4.47 72.2±5.92 73.3±5.76       
GLB day 0 27.6±2.97 28.9±5.11 28.6±3.43 0.461 0.978 0.234 
  day 180 28.1±3.09 28.4±3.96 28.5±3.93       
ALB day 0 43.1±2.92 43.2±3.15 44.0±3.01 0.881 0.032 0.308 
  day 180 42.7±2.9 43.1±3.04 44.7±5.2       
Values are presented as mean ± SD. Groups sharing the same superscript (a or b) have no 
significant difference from each other in the post-hoc analysis (P≥0.05). BUN, blood urea 
nitrogen; ALT, alanine transaminase; AST, aspartate transaminase; TBIL, total bilirubin; 
DBIL, direct bilirubin; IBIL, indirect bilirubin; TP, total protein; GLB, globin-like protein; 
ALB, albumin. 
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Figure legends 
Figure 1 Flow chart of present randomized controlled trial. 
 
Figure 2 Effect of n-3 PUFA supplements on erythrocyte phospholipid n-3 fatty acid 
compositions. Groups sharing the same superscript (a or b) have no significant difference 
from each other in the post-hoc analysis (P≥0.05), after adjustment for age, sex, study center 
and baseline BMI and baseline corresponding fatty acid composition. ALA, alpha-linolenic 
acid (C18:3n3); EPA, eicosapentaenoic acid (C20:5n3); DHA, docosahexaenoic acid 
(C22:6n3). 
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Figure 2 Effect of n-3 PUFA supplements on erythrocyte phospholipid n-3 fatty acid compositions  
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